Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis
Jian Luo, Peggy P. Ho, Marion S. Buckwalter, Tiffany Hsu, Lowen Y. Lee, Hui Zhang, Dae-Kee Kim, Seong-Jin Kim, Sanjiv S. Gambhir, Lawrence Steinman, Tony Wyss-Coray
Jian Luo, Peggy P. Ho, Marion S. Buckwalter, Tiffany Hsu, Lowen Y. Lee, Hui Zhang, Dae-Kee Kim, Seong-Jin Kim, Sanjiv S. Gambhir, Lawrence Steinman, Tony Wyss-Coray
View: Text | PDF
Research Article Autoimmunity

Glia-dependent TGF-β signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis

  • Text
  • PDF
Abstract

Autoimmune encephalomyelitis, a mouse model for multiple sclerosis, is characterized by the activation of immune cells, demyelination of axons in the CNS, and paralysis. We found that TGF-β1 synthesis in glial cells and TGF-β–induced signaling in the CNS were activated several days before the onset of paralysis in mice with autoimmune encephalomyelitis. While early production of TGF-β1 was observed in glial cells TGF-β signaling was activated in neurons and later in infiltrating T cells in inflammatory lesions. Systemic treatment with a pharmacological inhibitor of TGF-β signaling ameliorated the paralytic disease and reduced the accumulation of pathogenic T cells and expression of IL-6 in the CNS. Priming of peripheral T cells was not altered, nor was the generation of TH17 cells, indicating that this effect was directed within the brain, yet affected the immune system. These results suggest that early production of TGF-β1 in the CNS creates a permissive and dangerous environment for the initiation of autoimmune inflammation, providing a rare example of the brain modulating the immune system. Importantly, inhibition of TGF-β signaling may have benefits in the treatment of the acute phase of autoimmune CNS inflammation.

Authors

Jian Luo, Peggy P. Ho, Marion S. Buckwalter, Tiffany Hsu, Lowen Y. Lee, Hui Zhang, Dae-Kee Kim, Seong-Jin Kim, Sanjiv S. Gambhir, Lawrence Steinman, Tony Wyss-Coray

×

Figure 7

Treatment of IN-1130 inhibits TGF-β signaling but does not significantly affect the distribution of CD4 T cell subsets with activated TGF-β signaling.

Options: View larger image (or click on image) Download as PowerPoint
Treatment of IN-1130 inhibits TGF-β signaling but does not significantly...
(A and B) Activation of TGF-β signaling in lymphocytes from spleen sections of SBE-luRT mice with EAE (B) or no disease (A). Spleens were cut transversely at 40 μm and the sections were stained for RFP (brain sections of the same mice are shown in Figure 3). (C–F) Flow cytometry analysis of T cells isolated from the spinal cord and spleen of IN-1130 or PBS-treated SBE-lucRT mice at 14 dpi (n = 5 mice per group combined). Cells were stained with antibodies against RFP in combination with CD4, IL-4, IFN-γ, Foxp3, and IL-17. (C) IN-1130 significantly inhibits RFP expression in CD4+ T cells isolated from spinal cord (top panel) or spleen (bottom panel; FlowJo population comparison; T(X) = 39.7 for spinal cord, 1,240 for spleen). (D) Dot plots of all RFP+ cells expressing IL-17. (E and F) Percentages of RFP+ cells expressing the indicated intracellular markers in the spinal cord (E) and spleen (F). No significant differences were observed in any of the percentages between IN-1130 (black bars) and PBS-treated (white bars) mice by FlowJo population comparison; T(X) = 0.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts